pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX
TENAX THERAPEUTICS
TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Chapel Hill, USA
- Employees
- 19
- Programs
- 7
- Drugs
- 2
- Patents
- 4
TENAX THERAPEUTICS patents
4 pharmaceutical patents indexed for TENAX THERAPEUTICS. 0 expire within 24 months.
TENAX THERAPEUTICS has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11969424
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11701355
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11607412
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
granted
Frequently asked questions
How many patents does TENAX THERAPEUTICS have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do TENAX THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.